litlas
Log inCreate account

Aňa Lluch

Active 1994–2024

Also published as
Ana Lluch
108
Papers
21,314
Citations
71
h-index
104
i10-index

Citations

Citations per year for Aňa Lluch1996: 1 citations1999: 3 citations2000: 4 citations2001: 4 citations2002: 4 citations2003: 11 citations2004: 18 citations2005: 27 citations2006: 45 citations2007: 60 citations2008: 68 citations2009: 118 citations2010: 164 citations2011: 172 citations2012: 204 citations2013: 205 citations2014: 244 citations2015: 208 citations2016: 197 citations2017: 219 citations2018: 189 citations2019: 610 citations2020: 687 citations2021: 810 citations2022: 643 citations2023: 474 citations2024: 712 citations2025: 321 citations2026: 9 citations1997–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,281 citing papers, 24% of this breakdownChina: 1,090 citing papers, 11.5% of this breakdownItaly: 588 citing papers, 6.2% of this breakdownSpain: 523 citing papers, 5.5% of this breakdownUnited Kingdom: 518 citing papers, 5.5% of this breakdownGermany: 417 citing papers, 4.4% of this breakdownFrance: 353 citing papers, 3.7% of this breakdownCanada: 273 citing papers, 2.9% of this breakdownSwitzerland: 231 citing papers, 2.4% of this breakdownBelgium: 226 citing papers, 2.4% of this breakdownSouth Korea: 226 citing papers, 2.4% of this breakdownAustralia: 225 citing papers, 2.4% of this breakdown
0%24%Other 26.7%

Institutions

Fields

  • Medicine49.9%
  • Biochemistry, Genetics and Molecular Biology42.7%
  • Immunology and Microbiology2.4%
  • Computer Science1.1%
  • Engineering1%
  • Materials Science0.8%
  • Other2.1%

Topics

  • HER2/EGFR in Cancer Research9.4%
  • Breast Cancer Treatment Studies9.2%
  • Advanced Breast Cancer Therapies4.6%
  • Cancer Cells and Metastasis3.8%
  • Cancer Treatment and Pharmacology3.3%
  • Cancer Genomics and Diagnostics2.8%
  • Other66.9%

Coauthors

All papers

Open in search
  1. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Authors: Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Esther Barnadas, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Aňa Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat - npj Breast Cancer 2021 cited by 691

  2. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Laslo Roman, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2011 cited by 2,358

  3. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

    Authors: Kyung‐min Lee, Jennifer M. Giltnane, Justin M. Balko, Luis J. Schwarz, Ángel Guerrero‐Zotano, Katherine E. Hutchinson, Mellissa J. Nixon, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Taekyu Lee, Henry Gómez, Aňa Lluch, José Alejandro Pérez Fidalgo, Melissa M. Wolf, Gabriela Andrejeva, Jeffrey C. Rathmell, Stephen W. Fesik, Carlos L. Arteaga - Cell Metabolism 2017 cited by 646

  4. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Domenico Magazzù, Virginia McNally, Hannah Douthwaite, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2016 cited by 874

  5. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    Authors: Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga - The Lancet 2010 cited by 1,268

  6. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

    Authors: Katherine Stemke‐Hale, Ana M. González-Angulo, Aňa Lluch, Richard M. Neve, Wen-Lin Kuo, Michael A. Davies, Mark Carey, Zhi Hu, Yinghui Guan, Ayşegül A. Şahin, W. Fraser Symmans, Lajos Pusztai, Laura K. Nolden, Hugo M. Horlings, Katrien Berns, Mien‐Chie Hung, Marc J. van de Vijver, Vicente Valero, Joe W. Gray, René Bernards, Gordon B. Mills, Bryan T. Hennessy - Cancer Research 2008 cited by 1,043

  7. Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells

    Authors: Sara S. Oltra, Sara Colomo, Laura Sin, María Pérez-López, Sara Lázaro, Ángela Molina-Crespo, Kyoung-Han Choi, David Ros‐Pardo, Lidia Martínez, Saleta Morales, Cristina González-Paramos, Alba Orantes, Mario Soriano‐Navarro, Alberto Hernández, Aňa Lluch, Federico Rojo, Joan Albanell, Paulino Gómez‐Puertas, Jae‐Kyun Ko, David Sarrió, Gema Moreno‐Bueno - Cell Death and Differentiation 2023 cited by 77

  8. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

    Authors: Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, Susana García‐Recio, Octavio Burgués Gasión, Laia Paré, Silvia Antolín, Rosella Martinello, Isabel Blancas, Bárbara Adamo, Ángel Guerrero‐Zotano, Montserrat Muñoz-Mateu, Paolo Nucíforo, María Vidal, Ramón M. Pérez, José I. Chacón López-Muniz, Rosalía Caballero, Vicente Peg, Eva Carrasco, Federico Rojo, Charles M. Perou, Javier Cortés, Vincenzo Adamo, Joan Albanell, Roger R. Gomis, Aňa Lluch, Aleix Prat - Cancer Research 2017 cited by 251

  9. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    Authors: Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga - The Lancet Oncology 2014 cited by 491

  10. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Authors: Susana García‐Recio, Aatish Thennavan, Michael P. East, Joel S. Parker, Juan Miguel Cejalvo, Joseph P. Garay, Daniel P. Hollern, Xiaping He, Kevin R. Mott, Patricia Galván, Cheng Fan, Sara R. Selitsky, Alisha R. Coffey, David Marron, Fara Brasó‐Maristany, Octavio Burgués, Joan Albanell, Federico Rojo, Aňa Lluch, Eduardo Martínez de Dueñas, Jeffery M. Rosen, Gary L. Johnson, Lisa A. Carey, Aleix Prat, Charles M. Perou - Journal of Clinical Investigation 2020 cited by 110

  11. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

    Authors: Pîlar Eroles, Ana Bosch, José Alejandro Pérez Fidalgo, Aňa Lluch - Cancer Treatment Reviews 2011 cited by 625

  12. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

    Authors: Aura Muntasell, Federico Rojo, Sònia Servitja, Carlota Rubio-Pérez, Mariona Cabo, David Tamborero, Marcel Costa-García, Maria Martinez‐García, Sílvia Menéndez, Ivonne Vázquez, Aňa Lluch, Abel González-Pérez, Ana Rovira, Miguel López‐Botet, Joan Albanell - Clinical Cancer Research 2019 cited by 131

  13. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

    Authors: MohammadA Sabbaghi, Gabriel Gil‐Gómez, Cristina Guardia, Sònia Servitja, Oriol Arpí, Sara García‐Alonso, Sílvia Menéndez, Montserrat Arumí-Uría, Laia Serrano, Marta Salido, Aura Muntasell, Maria Martinez‐García, Sandra Zazo, Cristina Chamizo, Paula Gónzález-Alonso, Juan Madoz‐Gúrpide, Pîlar Eroles, Joaquı́n Arribas, Ignasi Tusquets, Aňa Lluch, Atanasio Pandiella, Federico Rojo, Ana Rovira, Joan Albanell - Clinical Cancer Research 2017 cited by 96

  14. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Authors: Ángela Santonja, Alfonso Sánchez‐Muñoz, Aňa Lluch, M Rosario Chica-Parrado, Joan Albanell, José Ignacio Chacón, Silvia Antolín, José M. Jerez, Juan de la Haba-Rodríguez, Vanessa de Luque, Cristina Elisabeth Fernández-De Sousa, Luís Vicioso, Y. Plata, César L. Ramírez-Tortosa, Martina Álvarez, Casilda Llácer, Irene Zarcos‐Pedrinaci, Eva Carrasco, Rosalía Caballero, Miguel Martín, Emilio Alba - Oncotarget 2018 cited by 186

  15. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

    Authors: Cristina Hernándo, Belén Ortega, Marta Tapia, Santiago Moragón, María Teresa Martínez, Pîlar Eroles, Iris Garrido‐Cano, Anna Adam‐Artigues, Aňa Lluch, Begoña Bermejo, Juan Miguel Cejalvo - International Journal of Molecular Sciences 2021 cited by 129

  16. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

    Authors: Patricia Fernández‐Nogueira, Mario Mancino, Gemma Fuster, Anna López‐Plana, Patricia Jáuregui, Vanesa Almendro, Estel Enreig, Sílvia Menéndez, Federico Rojo, Aleix Noguera‐Castells, Anke Bill, L. Alex Gaither, Laia Serrano, Leire Recalde‐Percaz, Núria Moragas, Raúl Alonso, Elisabet Ametller, Ana Rovira, Aňa Lluch, Joan Albanell, Pere Gascón, Paloma Bragado - Clinical Cancer Research 2019 cited by 109

  17. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

    Authors: Bryan T. Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke‐Hale, Michael Z. Gilcrease, Savitri Krishnamurthy, Ju‐Seog Lee, Jane Fridlyand, Ayşegül A. Şahin, Roshan Agarwal, Corwin Joy, Wenbin Liu, David Stivers, Keith Baggerly, Mark Carey, Aňa Lluch, Carlos Monteagudo, Xiaping He, Victor Weigman, Cheng Fan, Juan Palazzo, Gabriel N. Hortobágyi, Laura K. Nolden, Nicholas J. Wang, Vicente Valero, Joe W. Gray, Charles M. Perou, Gordon B. Mills - Cancer Research 2009 cited by 857

  18. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Authors: Anna Adam‐Artigues, Enrique J. Arenas, Alex Martínez-Sabadell, Fara Brasó‐Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernándo, María Teresa Martínez, Juan Antonio Carbonell‐Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Aňa Lluch, Aleix Prat, Joaquı́n Arribas, Pîlar Eroles, Juan Miguel Cejalvo - Science Advances 2022 cited by 56

  19. Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

    Authors: Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Aňa Lluch, Begoña Bermejo, Félix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez, Pîlar Eroles - ACS Applied Materials & Interfaces 2023 cited by 37

  20. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

    Authors: Meritxell Bellet, Kathryn P. Gray, Prudence A. Francis, István Láng, Eva Ciruelos, Aňa Lluch, Miguel Ángel Climent, Gustavo Catalán, Antoni Avellà, Uriel Bohn, Antonio González-Martı́n, Roser Ferrer, Roberto Catalán, Analía Azaro, Agnita Rajasekaran, Josefa Morales, Josep Vázquez, Gini F. Fleming, Karen N. Price, Meredith M. Regan - Journal of Clinical Oncology 2016 cited by 157

  21. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies

    Authors: Marta Tapia, Cristina Hernándo, María Teresa Martínez, Octavio Burgués, Cristina Tebar-Sánchez, Ana Lameirinhas, Anna Ágreda‐Roca, Sandra Torres‐Ruiz, Iris Garrido‐Cano, Aňa Lluch, Begoña Bermejo, Pîlar Eroles - Cancers 2023 cited by 41

  22. Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study

    Authors: Adela Castelló, Marina Pollán, Brian Buijsse, A. Ruíz, Ana Casas, José Manuel Baena-Cañada, Virginia Lope, Silvia Antolín, Manuel Ramos, Montserrat Muñoz-Mateu, Aňa Lluch, Ana de Juan-Ferré, Carlos Jara, M. Jimeno, Petra Rosado, Elena Dı́az, Vicente Guillém, Eva Carrasco, Beatriz Pérez‐Gómez, Jesús Vioqué, Heiner Boeing, Miguel Martín - British Journal of Cancer 2014 cited by 181

  23. High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients

    Authors: Chandra Bartholomeusz, Ana M. González-Angulo, Ping Liu, Naoki Hayashi, Aňa Lluch, Jaime Ferrer-Lozano, Gabriel N. Hortobágyi - The Oncologist 2012 cited by 153

  24. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

    Authors: Sylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio, Enrique J. Arenas, Fernando Salvador, Jelena Urosevic, Cristina Figueras-Puig, Federico Rojo, Iván del Barco Barrantes, Juan Miguel Cejalvo, Marta Palafox, Marc Guiu, Antonio Berenguer, Aikaterini Symeonidi, Anna Bellmunt, Daniela Kalafatović, Anna Arnal Estape, Esther Fernández, Barbara Müllauer, Rianne Groeneveld, Konstantin Slobodnyuk, Camille Stephan‐Otto Attolini, Cristina Saura, Joaquı́n Arribas, Javier Cortés, Ana Rovira, Montse Muñoz, Aňa Lluch, Violeta Serra, Joan Albanell, Aleix Prat, Ángel R. Nebreda, Salvador Aznar Benitah, Roger R. Gomis - Nature Cell Biology 2018 cited by 130